REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Shield KD, Ferlay J, Jemal A, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin 2017;67:51-64.
3. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
5. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
6. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
7. Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol 2003;15:S37-50.
9. Strojan P, Hutcheson KA, Eisbruch A, et al. Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev 2017;59:79-92.
10. Yildiz E, Grasl S, Denk-Linnert DM, et al. Long-term swallowing outcome and dysphagia in advanced staged head and neck squamous cell carcinomas after radiotherapy. J Clin Med 2022;11:2688.
11. Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 1995;31:1141-64.
12. Kouloulias V, Thalassinou S, Platoni K, et al. The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: a systematic review with dosimetric and clinical parameters. Biomed Res Int 2013;2013:401261.
13. Nepon H, Safran T, Reece EM, Murphy AM, Vorstenbosch J, Davison PG. Radiation-induced tissue damage: clinical consequences and current treatment options. Semin Plast Surg 2021;35:181-8.
14. Lane SA, Slater JM, Yang GY. Image-guided proton therapy: a comprehensive review. Cancers 2023;15:2555.
15. Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: a major driver of resistance even for novel radiotherapy modalities. Semin Cancer Biol 2024;98:19-30.
16. Sminia P, Guipaud O, Viktorsson K, et al. Clinical radiobiology for radiation oncology. In: Baatout S, editor. Radiobiology textbook. Cham: Springer International Publishing; 2023. pp. 237-309.
17. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212.
18. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008;26:3770-6.
19. Blanchard P, Gunn GB, Lin A, Foote RL, Lee NY, Frank SJ. Proton therapy for head and neck cancers. Semin Radiat Oncol 2018;28:53-63.
20. Kiafi P, Kouri MA, Patatoukas G, et al. Unravelling quality of life for head and neck cancer patients after VMAT radiation therapy: insights from toxicity, dosimetry and symptoms correlation. Clin Pract 2024;14:1085-99.
21. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012;30:4249-55.
22. Sari S, Beduk Esen CS, Yazici G, Yuce D, Cengiz M, Ozyigit G. Do grape and black mulberry molasses have an effect on oral mucositis and quality of life in patients with head and neck cancer? Support Care Cancer 2022;30:327-36.
23. Liao KC, Chuang HC, Chien CY, et al. Quality of life as a mediator between cancer stage and long-term mortality in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy. Cancers 2021;13:5063.
24. Van den Bosch L, van der Laan HP, van der Schaaf A, et al. Patient-reported toxicity and quality-of-life profiles in patients with head and neck cancer treated with definitive radiation therapy or chemoradiation. Int J Radiat Oncol Biol Phys 2021;111:456-67.
25. Viganò A, De Felice F, Iacovelli NA, et al. M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy ± systemic therapy - A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Oral Oncol 2021;115:105189.
26. Xu MJ, Plonowska KA, Gurman ZR, et al. Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. Laryngoscope 2020;130:E48-56.
27. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007;29:923-31.
28. Pocobelli G, Ziebell R, Fujii M, et al. Symptom burden in long-term survivors of head and neck cancer: patient-reported versus clinical data. EGEMS 2019;7:25.
29. Tuomi L, Fransson P, Wennerberg J, Finizia C. A longitudinal study of the Swedish MD anderson dysphagia inventory in patients with oral cancer. Laryngoscope Investig Otolaryngol 2020;5:1125-32.
30. Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights 2013;6:61-8.
31. Klimek L, Bergmann KC, Biedermann T, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int 2017;26:16-24.
32. Åström M, Thet Lwin ZM, Teni FS, Burström K, Berg J. Use of the visual analogue scale for health state valuation: a scoping review. Qual Life Res 2023;32:2719-29.
33. Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol 2016;2016:6186543.
34. Atkinson TM, Andreotti CF, Roberts KE, Saracino RM, Hernandez M, Basch E. The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. Support Care Cancer 2015;23:3645-52.
35. der Laan HP, Van den Bosch L, Schuit E, Steenbakkers RJHM, van der Schaaf A, Langendijk JA. Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer. Radiother Oncol 2021;160:47-53.
36. Cengiz M, Ozyar E, Esassolak M, et al. Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules. Int J Radiat Oncol Biol Phys 2005;63:1347-53.
37. Lu N, Qin T, Hu W. Impact of changes in psychological resilience during treatment with intensity-modulated radiotherapy on nasopharyngeal carcinoma patients: a prospective study. Ann Palliat Med 2022;11:123-34.
38. Stadler ME, Patel MR, Couch ME, Hayes DN. Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am 2008;22:1099-124, vii.
39. Vanderwaeren L, Dok R, Verstrepen K, Nuyts S. Clinical progress in proton radiotherapy: biological unknowns. Cancers 2021;13:604.
40. Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers. Br J Radiol 2012;85:487-94.
41. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011;84:967-96.
42. Cheng QR, Fan MX, Hao J. et al. Chest CT features of children infected by B.1.617.2 (Delta) variant of COVID-19. World J Pediatr 2022;18:37-42.
44. Kutuk T, Atak E, Villa A, Kalman NS, Kaiser A. Interdisciplinary collaboration in head and neck cancer care: optimizing oral health management for patients undergoing radiation therapy. Curr Oncol 2024;31:2092-108.
45. Moreno AC, Frank SJ, Garden AS, et al. Intensity modulated proton therapy (IMPT) - the future of IMRT for head and neck cancer. Oral Oncol 2019;88:66-74.
46. Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol 2016;120:48-55.
47. Grant SR, Grosshans DR, Bilton SD, et al. Proton versus conventional radiotherapy for pediatric salivary gland tumors: acute toxicity and dosimetric characteristics. Radiother Oncol 2015;116:309-15.
48. Ladra MM, Edgington SK, Mahajan A, et al. A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother Oncol 2014;113:77-83.
49. Holliday EB, Kocak-Uzel E, Feng L, et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: a case-matched control analysis. Med Dosim 2016;41:189-94.
50. Sio TT, Lin HK, Shi Q, et al. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes. Int J Radiat Oncol Biol Phys 2016;95:1107-14.
51. Embring A, Onjukka E, Mercke C, et al. Re-irradiation for head and neck cancer: cumulative dose to organs at risk and late side effects. Cancers 2021;13:3173.
52. Scartoni D, Giacomelli I, Pertile R, et al. Proton therapy re-irradiation provides promising clinical results in recurrent brain meningioma. Acta Oncol 2023;62:1096-101.
53. Ko M, Yang K, Ahn YC, et al. Dosimetric comparison and selection criteria of intensity-modulated proton therapy and intensity-modulated radiation therapy for adaptive Re-plan in T3-4 nasopharynx cancer patients. Cancers 2024;16:3402.
54. Hutcheson K, Lewin J, Garden A, et al. Early experience with IMPT for the treatment of oropharyngeal tumors: acute toxicities and swallowing-related outcomes. Int J Radiat Oncol Biol Phys 2013;87:S604.
55. Cao J, Zhang X, Jiang B, et al. Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiother Oncol 2021;160:32-9.
56. Grant SR, Hutcheson KA, Ye R, et al. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol 2020;148:133-9.
57. Thomson DJ, Cruickshank C, Baines H, et al. TORPEdO: a phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer. Clin Transl Radiat Oncol 2023;38:147-54.
58. Manzar GS, Lester SC, Routman DM, et al. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiother Oncol 2020;147:64-74.
59. Chou YC, Fan KH, Lin CY, et al. Intensity modulated proton beam therapy versus volumetric modulated arc therapy for patients with nasopharyngeal cancer: a propensity score-matched study. Cancers 2021;13:3555.
60. Góra J, Kuess P, Stock M, et al. ART for head and neck patients: on the difference between VMAT and IMPT. Acta Oncol 2015;54:1166-74.
61. Lattery G, Kaulfers T, Cheng C, et al. Pencil beam scanning bragg peak FLASH technique for ultra-high dose rate intensity-modulated proton therapy in early-stage breast cancer treatment. Cancers 2023;15:4560.
62. Sharma S, Zhou O, Thompson R, et al. Quality of life of postoperative photon versus proton radiation therapy for oropharynx cancer. Int J Part Ther 2018;5:11-7.
63. Swisher-McClure S, Teo BK, Kirk M, Chang C, Lin A. Comparison of pencil beam scanning proton- and photon-based techniques for carcinoma of the parotid. Int J Part Ther 2016;2:525-32.
